DAX®15.215,00-0,13%TecDAX®3.453,75-0,84%Dow Jones 3033.745,83-0,16%Nasdaq 10013.793,69-0,37%

BUSINESS WIRE: Sofinnova Partners Closes €445M ($540M) Oversubscribed Late-Stage Healthcare Crossover Fund

| Quelle: Business_Wire | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen


The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe

With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage


Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of the Sofinnova Crossover Fund at €445 million ($540 million USD). The fund was oversubscribed and significantly exceeded its target. This capital raise positions Sofinnova Partners as the largest crossover investor in Europe dedicated to late-stage biopharma and medtech investments.

The fund will maintain its focus on European clinical-stage companies needing scale-up capital and will also support best-in-class companies in the U.S. and elsewhere. The fund has, to date, invested in 10 high-profile companies developing unique products that address major unmet clinical needs. The initial portfolio has demonstrated outstanding progress since inception, with the majority of investments reaching positive clinical trial milestones and raising large financings, including two NASDAQ IPOs of European companies.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “European biopharma and medtech companies have matured tremendously in the last decade. Sofinnova Partners was the first European VC to seize the opportunity to unlock the potential of these high-growth start-ups by providing late-stage capital, building on our decades of experience funding innovative life science companies. With over €2 billion of assets under management dedicated to life science investing and an outstanding international team, Sofinnova Partners continues its expansion to partner with ambitious entrepreneurs across Europe, from company creation to late-stage developments.”

Cédric Moreau, Partner in the Sofinnova Crossover Fund, commented: “We are grateful for the continuing support of our existing and new limited partners from all over the world who have helped us reach a target significantly beyond our initial objectives. The Sofinnova Crossover Fund is the largest of its kind in Europe and the only one with a team solely dedicated to growth-stage opportunities in healthcare. There has never been more awareness of the importance of investing in our collective health and future, and we are honored to contribute to this endeavor through this fund strategy.”

The Sofinnova Crossover Fund was recognized as a front runner in this domain in the 2019 “Tibi Report” commissioned by the French government as an initiative to fuel later-stage companies in Europe.1 It was subsequently granted the “Tibi” designation, making it eligible to apply for access to €6 billion in funds earmarked for this objective, which helped attract key French institutions as limited partners.

The Sofinnova Crossover Fund has expanded its team recently and, operating from Paris and London, continues to see an exceptional flow of new investment opportunities, bolstered by the firm’s extensive global network, its leading role in Europe, and the strength of its multi-fund life sciences strategy.

Triago acted as placement agent and Clifford Chance acted as legal counsel.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com

1 The Tibi Report was written by the Professor of Economics, Philippe Tibi, who highlighted the crucial need for scale-up financing for high-growth companies in France and Europe.

Bommy Lee
Head of Communications, Sofinnova Partners
+33 (0) 6 47 71 38 11

North America
RooneyPartners LLC
Kate Barrette
+1 212 223 0561

Anne Rein
+33 (0) 6 03 35 92 05

Havas PR Milan
Rafaella Casula
+39 (0) 345 3780834


Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
21:09 BUSINESS WIRE: Halliburton stellt dem Norwegian Petroleum Directorate eine Plattform zur Verwaltung von Erdöldaten zur Verfügung
20:36 BUSINESS WIRE: La reputazione aziendale migliora in un anno di crisi, secondo The RepTrak Company
19:48 BUSINESS WIRE: Von der Fabrik direkt nach Hause – der intelligente, klappbare Staubsauger Redkey F10 bietet ein fantastisches Preis-Leistungs-Verhältnis
19:46 BUSINESS WIRE: Visit Argentina: Il calcio in Argentina - una passione portegna
19:15 BUSINESS WIRE: Die Securities Litigation Group der Kanzlei Kim Spencer McPhee Barristers PC, ehemals Morganti & Co., PC, gibt bekannt, dass der Oberste Gerichtshof von Ontario („das Gericht“) den in der Sammelklage gegen Colt Resources Inc.
19:13 BUSINESS WIRE: Halliburton fornirà la piattaforma per la gestione dei dati petroliferi alla Direzione norvegese per il petrolio
19:10 BUSINESS WIRE: Riffyn lancia Riffyn Nexus v4.2 per rafforzare l’integrità dei dati relativi ai bioprocessi attraverso la convalida automatizzata
19:08 BUSINESS WIRE: Mirum Pharmaceuticals e Vivet Therapeutics stipulano un accordo esclusivo di opzione e licenza di respiro mondiale per i programmi di terapia genica di Vivet per il trattamento della colestasi intraepatica familiare progressiva
19:05 BUSINESS WIRE: Globality e BT Sourced annunciano una nuova collaborazione per sprigionare il potere dell’approvvigionamento
19:04 BUSINESS WIRE: Sierra Metals veröffentlicht am Donnerstag, 6. Mai 2021, die konsolidierten Geschäftsergebnisse für das erste Quartal 2021
Rubrik: Finanzmarkt
21:34 DGAP-DD: Zalando SE (deutsch) Zalando SE 85,76 -2,39%
21:33 Devisen: Eurokurs kaum bewegt EUR/USD Wechselkurs: Euro / US Dollar 1,1908 +0,1232%
21:31 DGAP-DD: Zalando SE (deutsch) Zalando SE 85,76 -2,39%
21:28 DGAP-DD: Zalando SE (deutsch) Zalando SE 85,76 -2,39%
21:24 DGAP-DD: Zalando SE (deutsch) Zalando SE 85,76 -2,39%
21:21 EU verschärft Iran-Sanktionen wegen Menschenrechtsverletzungen
21:20 IRW-News: Marble Financial Inc.: Marble Financial schließt den Erwerb von Inverite Verifications Inc. ab MARBLE FINANCIAL INC. 0,183 +16,560%
21:19 DGAP-DD: Zalando SE (deutsch) Zalando SE 85,76 -2,39%
21:17 DGAP-Adhoc: Deutsche Beteiligungs AG: Bezugsrechtskapitalerhöhung um bis zu 3.760.998 neue Aktien beschlossen (deutsch) Deutsche Beteiligungs AG 40,50 -1,82%
21:13 DGAP-Adhoc: Eckert & Ziegler erhält Vertriebslizenz für Technetium-Generatoren in Brasilien (deutsch) Eckert & Ziegler AG 69,95 -2,24%



Aktuelle Videos

HSBC Trading TV



Börsen & Märkte


zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 15 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen